least one of the amino groups of the polycationic aliphatic amine is a secondary amino group. In some examples, the polycationic aliphatic amine is selected from the group consisting of putrescine, spermidine, spermine and combinations thereof.

[0010] In some examples, the pharmaceutically effective amount of polycationic aliphatic amine is between about 3 mmol to 12 mmol.

[0011] In a further aspect, there is provided a method of reducing or preventing darkening of the skin and/or melanogenesis, the method comprising administering at least one inhibitor of polycationic aliphatic amine in a pharmaceutically effective amount to a subject in need thereof.

[0011a] In some examples, there is provided a use of at least one inhibitor of polycationic aliphatic amine in the manufacture of a medicament for reducing darkening of the skin and/or melanogenesis.

[0011b] In some examples, there is provided a use of at least one ornithine decarboxylase 1 (ODC1) inhibitor in the manufacture of a medicament for reducing darkening of the skin and/or melanogenesis, wherein the medicament is to be administered to a subject in need thereof, wherein the subject is suffering from melasma, post inflammatory hyperpigmentation, or solar lentigo.

[0011c] In some examples, there is provided a use of a difluoromethylornithine (DFMO) in the manufacture of a medicament for reducing darkening of the skin and/or melanogenesis, wherein the medicament is to be administered to a subject in need thereof, wherein the subject is suffering from melasma, post inflammatory hyperpigmentation, or solar lentigo.

[0011d] In some examples, there is provided a cosmetic method of reducing darkening of the skin and/or melanogenesis, the method comprising administering at least one inhibitor of polycationic aliphatic amine in a pharmaceutically effective amount to a subject in need thereof.

[0012] In some examples, the subject is suffering from darkening of the skin and/or melanogenesis associated with pregnancy, inflammation, yeast infection, or aging.

[0013] In some examples, the at least one inhibitor of polycationic aliphatic amine is selected from the group consisting of: an inhibitor of the transport of polycationic aliphatic amine, an inhibitor of the synthesis of polycationic aliphatic amine, an inhibitor of the catabolism of polycationic aliphatic amine, and combinations thereof. In one example, the inhibitor of the transport of polycationic aliphatic amine is trimer44NMe. In another example,

the inhibitor of the synthesis of polycationic aliphatic amine is difluoromethylornithine (DFMO).

[0014] In some examples, the at least one polycationic aliphatic amine or the at least one inhibitor of polycationic aliphatic amine is administered in a pharmaceutical composition, wherein the pharmaceutical composition is administered intradermally, cutaneously, subcutaneously, topically, transdermally, or any combination thereof. In some examples, the pharmaceutical composition is provided as pastes, powders, dressings, creams, plasters, solutions, patches, gels, suspensions, aqueous liquid suspensions, non-aqueous liquid suspensions, oil-in-water emulsions, a water-in-oil liquid emulsions, solutions, sterile solids, crystalline solids, amorphous solids, solids for reconstitution or combinations thereof. In one example, the pharmaceutical composition is a dermatological composition.

[0015] In one example, the method provided herein is used for cosmetic purposes.

BRIEF DESCRIPTION OF THE DRAWINGS